131 related articles for article (PubMed ID: 28878027)
1. Death by HDAC Inhibition in Synovial Sarcoma Cells.
Laporte AN; Poulin NM; Barrott JJ; Wang XQ; Lorzadeh A; Vander Werff R; Jones KB; Underhill TM; Nielsen TO
Mol Cancer Ther; 2017 Dec; 16(12):2656-2667. PubMed ID: 28878027
[TBL] [Abstract][Full Text] [Related]
2. HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma.
Laporte AN; Barrott JJ; Yao RJ; Poulin NM; Brodin BA; Jones KB; Underhill TM; Nielsen TO
PLoS One; 2017; 12(1):e0169407. PubMed ID: 28056055
[TBL] [Abstract][Full Text] [Related]
3. EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor.
Su L; Cheng H; Sampaio AV; Nielsen TO; Underhill TM
Oncogene; 2010 Jul; 29(30):4352-61. PubMed ID: 20514024
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma.
Lanzi C; Favini E; Dal Bo L; Tortoreto M; Arrighetti N; Zaffaroni N; Cassinelli G
J Exp Clin Cancer Res; 2021 Dec; 40(1):381. PubMed ID: 34857011
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO
Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690
[TBL] [Abstract][Full Text] [Related]
6. Identification of cytotoxic agents disrupting synovial sarcoma oncoprotein interactions by proximity ligation assay.
Laporte AN; Ji JX; Ma L; Nielsen TO; Brodin BA
Oncotarget; 2016 Jun; 7(23):34384-94. PubMed ID: 27120803
[TBL] [Abstract][Full Text] [Related]
7. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
[TBL] [Abstract][Full Text] [Related]
8. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics.
Su L; Sampaio AV; Jones KB; Pacheco M; Goytain A; Lin S; Poulin N; Yi L; Rossi FM; Kast J; Capecchi MR; Underhill TM; Nielsen TO
Cancer Cell; 2012 Mar; 21(3):333-47. PubMed ID: 22439931
[TBL] [Abstract][Full Text] [Related]
9. Twist1 is essential in maintaining mesenchymal state and tumor-initiating properties in synovial sarcoma.
Lee KW; Lee NK; Ham S; Roh TY; Kim SH
Cancer Lett; 2014 Feb; 343(1):62-73. PubMed ID: 24051309
[TBL] [Abstract][Full Text] [Related]
10. Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth.
Törnkvist M; Natalishvili N; Xie Y; Girnita A; D'Arcy P; Brodin B; Axelson M; Girnita L
Biochem Biophys Res Commun; 2008 Apr; 368(3):793-800. PubMed ID: 18267106
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
[TBL] [Abstract][Full Text] [Related]
12. SRC signaling is crucial in the growth of synovial sarcoma cells.
Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
[TBL] [Abstract][Full Text] [Related]
13. Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo.
Ito T; Ouchida M; Morimoto Y; Yoshida A; Jitsumori Y; Ozaki T; Sonobe H; Inoue H; Shimizu K
Cancer Lett; 2005 Jun; 224(2):311-9. PubMed ID: 15914281
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial strategies to potentiate the efficacy of HDAC inhibitors in fusion-positive sarcomas.
Lanzi C; Cassinelli G
Biochem Pharmacol; 2022 Apr; 198():114944. PubMed ID: 35152144
[TBL] [Abstract][Full Text] [Related]
15. ETV4 and ETV5 drive synovial sarcoma through cell cycle and DUX4 embryonic pathway control.
DeSalvo J; Ban Y; Li L; Sun X; Jiang Z; Kerr DA; Khanlari M; Boulina M; Capecchi MR; Partanen JM; Chen L; Kondo T; Ornitz DM; Trent JC; Eid JE
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 33983905
[TBL] [Abstract][Full Text] [Related]
16. The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.
Banito A; Li X; Laporte AN; Roe JS; Sanchez-Vega F; Huang CH; Dancsok AR; Hatzi K; Chen CC; Tschaharganeh DF; Chandwani R; Tasdemir N; Jones KB; Capecchi MR; Vakoc CR; Schultz N; Ladanyi M; Nielsen TO; Lowe SW
Cancer Cell; 2018 Mar; 33(3):527-541.e8. PubMed ID: 29502955
[TBL] [Abstract][Full Text] [Related]
17. The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma.
Cironi L; Petricevic T; Fernandes Vieira V; Provero P; Fusco C; Cornaz S; Fregni G; Letovanec I; Aguet M; Stamenkovic I
Sci Rep; 2016 Feb; 6():22113. PubMed ID: 26905812
[TBL] [Abstract][Full Text] [Related]
18. SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.
Tamaki S; Fukuta M; Sekiguchi K; Jin Y; Nagata S; Hayakawa K; Hineno S; Okamoto T; Watanabe M; Woltjen K; Ikeya M; Kato T; Toguchida J
PLoS One; 2015; 10(11):e0142991. PubMed ID: 26571495
[TBL] [Abstract][Full Text] [Related]
19. Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma.
Jerby-Arnon L; Neftel C; Shore ME; Weisman HR; Mathewson ND; McBride MJ; Haas B; Izar B; Volorio A; Boulay G; Cironi L; Richman AR; Broye LC; Gurski JM; Luo CC; Mylvaganam R; Nguyen L; Mei S; Melms JC; Georgescu C; Cohen O; Buendia-Buendia JE; Segerstolpe A; Sud M; Cuoco MS; Labes D; Gritsch S; Zollinger DR; Ortogero N; Beechem JM; Petur Nielsen G; Chebib I; Nguyen-Ngoc T; Montemurro M; Cote GM; Choy E; Letovanec I; Cherix S; Wagle N; Sorger PK; Haynes AB; Mullen JT; Stamenkovic I; Rivera MN; Kadoch C; Wucherpfennig KW; Rozenblatt-Rosen O; Suvà ML; Riggi N; Regev A
Nat Med; 2021 Feb; 27(2):289-300. PubMed ID: 33495604
[TBL] [Abstract][Full Text] [Related]
20. Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy.
Nielsen TO; Poulin NM; Ladanyi M
Cancer Discov; 2015 Feb; 5(2):124-34. PubMed ID: 25614489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
